Société Reata Pharmaceuticals, Inc. Börse Stuttgart
Actions
2R3
US75615P1030
Recherche biotechnologique et médicale
Temps Différé
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
- EUR | -.--% | +0,63% | +373,53% |
2023 | Reata Pharmaceuticals, Inc. annonce des changements au sein de sa direction | CI |
2023 | Biogen : acquisition de Reata Pharmaceuticals finalisée | CF |
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
J. Huff
CEO | Chief Executive Officer | 70 | 01/09/22 |
Director of Finance/CFO | 60 | 26/09/23 | |
John Hunter
IRC | Investor Relations Contact | - | - |
Mike Visnick
PRN | Corporate Officer/Principal | - | 01/01/07 |
Robin Kral
PRN | Corporate Officer/Principal | - | 01/01/04 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
J. Huff
CEO | Chief Executive Officer | 70 | 01/09/22 |
Director/Board Member | - | 26/09/23 | |
Michael Dambach
BRD | Director/Board Member | - | 26/09/23 |
Robin Kramer
BRD | Director/Board Member | - | 26/09/23 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 3 | 4 515 246 | 0 | 0 | 75,54 % |
Action B | 1 | 33 331 586 | 28 588 243 ( 85,77 %) | 0 |
Coordonnées société
Secteur
Varia. 1 janv. | Capi. | |
---|---|---|
+11,60% | 106 Md | |
-4,68% | 24,28 Md | |
-0,82% | 21,96 Md | |
-10,12% | 18,16 Md | |
-42,12% | 16,37 Md | |
-17,47% | 15,56 Md | |
+2,77% | 13,63 Md | |
+34,58% | 12,27 Md | |
+77,64% | 8,87 Md |
- Bourse
- Actions
- Action RETA
- Action 2R3
- Société Reata Pharmaceuticals, Inc.